Case Study
Small Molecule Drug Design Service

Inquiry
Small Molecule Drug Design Service
AI-assisted small molecule discovery service

Small Molecule Drug Design Service for Hit Discovery, Lead Optimization & Candidate Prioritization

CD ComputaBio helps research teams transform target biology, structural information, assay data, and chemical ideas into decision-ready small molecule design plans. Our service connects structure-based design, ligand-based modeling, AI generation, virtual screening, molecular docking, molecular dynamics, ADMET prediction, and medicinal chemistry interpretation to support faster hit-to-lead and lead optimization projects.

Request a Drug Design Plan Compare Design Methods See Deliverables
Structure-based design Ligand-based modeling AI & de novo design ADMET-aware optimization
🎯
From target hypothesis to molecular design
Start from a protein structure, known ligand, active series, phenotype hit, disease pathway, or screening result.
🧪
Designs that support synthesis and testing
Prioritize compounds by binding mode, novelty, synthetic feasibility, physicochemical properties, and developability.
📊
Decision-ready scientific report
Receive ranked candidates, visual models, method notes, risk flags, and suggested next-step experiments.

What This Service Helps You Decide

Hit discovery

Which chemical starting points are worth testing?

Design or identify compounds with plausible binding modes, chemical diversity, target relevance, and practical follow-up potential.

Lead optimization

How should a hit be modified?

Guide analog design using SAR, docking poses, interaction hotspots, ADMET liabilities, selectivity goals, and medicinal chemistry constraints.

Candidate triage

Which molecules should move forward first?

Rank compounds by potency hypothesis, binding stability, physicochemical profile, toxicity risk, novelty, and synthesis feasibility.

Ask for Project Guidance

Small Molecule Drug Design Service Coverage

Structure-based

Structure-Based Drug Design

For projects with a crystal structure, cryo-EM structure, homology model, AlphaFold model, or binding site information.

  • Binding pocket characterization
  • Protein-small molecule docking
  • Interaction hotspot mapping
  • Pose validation and binding mode comparison
  • Analog and scaffold design around key residues
Ligand-based

Ligand-Based Drug Design

For projects with known active compounds, dose-response data, hit series, or public bioactivity records.

  • 2D/3D-QSAR modeling
  • Pharmacophore modeling
  • Similarity and scaffold analysis
  • R-group decomposition
  • Potency and property trend interpretation
AI design

De Novo Drug Design

For teams seeking new chemical matter, constrained analogs, patent-space expansion, or multi-objective optimization.

  • AI-generated candidate structures
  • Fragment growing and linking
  • Scaffold hopping
  • Property-constrained molecular generation
  • Diversity clustering and shortlist selection
Screening

Virtual Screening

For commercial libraries, natural product collections, focused libraries, or client-provided compound sets.

  • Structure-based virtual screening
  • Ligand-based virtual screening
  • Pharmacophore-based screening
  • Fragment library prioritization
  • Post-screening clustering and triage
Optimization

ADMET Prediction

Designed molecules are filtered for developability instead of binding score alone.

  • Solubility, permeability, and logP/logD evaluation
  • CYP and hERG risk prediction
  • PAINS and reactive group flagging
  • Metabolic liability review
  • Drug-likeness and lead-likeness assessment
Mechanism

Binding Free Energy Analysis

For high-value molecules requiring stronger confidence before synthesis or assays.

  • Molecular dynamics simulation
  • MM-PBSA/MM-GBSA analysis
  • Interaction persistence analysis
  • Water network and conformational change review
  • Mutation or selectivity hypothesis testing

Comparison of Small Molecule Design Methods

Application Scenario / Project Need Recommended Design Method Best Input Data Typical Output Useful Next Step
  • Target structure is available
  • Binding site is known
  • Need a target-guided binding hypothesis
 Structure-Based Drug Design PDB/model, active site residues, reference ligand, cofactors Binding modes, interaction map, ranked analogs, structure-guided design rationale Synthesis of top analogs or MD validation
  • Known active compounds exist
  • Target structure is unavailable or uncertain
  • Need SAR-driven optimization
 Ligand-Based Drug Design Active/inactive compounds, IC50/EC50/Ki values, assay notes SAR model, pharmacophore hypothesis, prioritized analogs Focused library synthesis or virtual screening
  • Need novel chemical matter
  • Current scaffold has IP or liability concerns
  • Need property-constrained generation
 De Novo Drug Design Target pocket, reference ligand, excluded scaffolds, property constraints Novel structures, scaffold families, diversity clusters, synthesis notes Patent-space review and focused synthesis
  • Large compound set needs prioritization
  • Need purchasable or testable hits
  • Need chemical diversity
 Virtual Screening SDF/SMILES library, target structure or ligand query, screening criteria Shortlisted compounds, cluster representatives, purchase/synthesis suggestions Experimental screening of top-ranked molecules
  • Weak hit needs potency improvement
  • Selectivity and ADMET need balancing
  • Need a synthesis matrix
 Hit-to-Lead Optimization with ADMET Prediction Hit structure, SAR data, target/off-target information, ADMET concerns Analog matrix, modification rationale, selectivity and developability ranking Biochemical or cellular assay validation
  • High-value candidates need stronger confidence
  • Docking poses require validation
  • Binding stability needs comparison
 MD Simulation and Binding Free Energy Analysis Prepared complexes, candidate list, protein environment, comparison groups Stability analysis, interaction persistence, free-energy estimates, mechanism notes Lead selection or deeper optimization

Choose a method based on: target information, ligand data, discovery stage, chemical novelty requirement, ADMET risk, synthesis plan, budget and timeline.

Choose the Right Design Method for My Project

Integrated Small Molecule Design Workflow

Project intake and scientific objective definition

Clarify whether the goal is hit discovery, scaffold replacement, potency improvement, selectivity design, ADMET optimization, mechanism exploration, or compound prioritization.

Target, ligand, and data preparation

Standardize protein structures, docking poses, ligand files, compound libraries, bioactivity values, and assay context for modeling and comparison.

Pocket, SAR, and chemical space analysis

Evaluate binding-site properties, ligand efficiency, key interaction patterns, scaffold diversity, activity cliffs, and property trends.

Molecular design and virtual generation

Generate candidate molecules through analog design, fragment-based design, scaffold hopping, AI generation, or focused library construction.

Computational evaluation and multiparameter filtering

Assess designed molecules by docking, pharmacophore fit, QSAR prediction, ADMET prediction, novelty checks, synthetic feasibility, and optional binding free energy analysis.

Ranking, reporting, and next-step recommendations

Deliver a prioritized compound list with design rationale, visual evidence, property flags, and recommended synthesis or assay strategy.

Start a Project Review

Input Data You Can Provide

  • Protein structure, AlphaFold model, homology model, or binding pocket residues
  • Known ligand, co-crystal ligand, inhibitor, substrate, fragment, or reference compound
  • Compound files in SMILES, SDF, MOL2, CSV, or vendor library format
  • Bioactivity values such as IC50, EC50, Ki, Kd, inhibition rate, or phenotypic readout
  • Known SAR, active/inactive compound labels, or medicinal chemistry notes
  • Design constraints such as MW, logP, TPSA, solubility, selectivity, IP space, or excluded motifs
  • Preferred experimental assay, disease context, target family, or downstream validation plan

What You Will Receive

  • Curated and prepared target/ligand data package
  • Binding pocket, pharmacophore, or SAR interpretation depending on project type
  • Ranked small molecule candidates with predicted binding modes or design rationale
  • Compound property table including physicochemical and ADMET prediction indicators
  • Interaction diagrams, 2D/3D visualizations, and representative molecular models
  • Risk flags for reactive groups, PAINS-like motifs, poor solubility, high lipophilicity, or toxicity alerts
  • Final report with scientific conclusions and recommended next-step experiments
Check My Input Data

Representative Project Scenarios

Scenario 1

Hit Identification for a New Target

Client need: find tractable starting compounds for a protein target with a predicted binding pocket.

  • Pocket preparation and druggability review
  • Focused virtual screening
  • Docking pose analysis and cluster selection
  • Top compound list for purchase or synthesis
Scenario 2

Lead Optimization for an Active Series

Client need: improve potency and selectivity while avoiding ADMET liabilities.

  • SAR and R-group decomposition
  • Analog design around key interaction hotspots
  • ADMET prediction and physicochemical property filtering
  • Prioritized synthesis matrix
Scenario 3

Scaffold Hopping for Novel IP Space

Client need: retain biological hypothesis while moving away from a crowded or problematic scaffold.

  • Pharmacophore and shape-based design
  • Core replacement and fragment recombination
  • Novelty and property triage
  • Mechanistic binding mode review
Request a Case-Matched Plan

Experimental Validation Support for Small Molecule Drug Design

Computational small molecule design helps prioritize compounds, analogs, binding hypotheses, and ADMET risks before synthesis or testing. To make these design results more actionable, CD ComputaBio can support wet-lab validation planning and coordinated experimental services for hit confirmation, activity testing, dose-response evaluation, selectivity assessment, and early developability review.

From design to evidence

Move from molecular ideas to experimentally supported decisions

Docking scores, AI-generated molecules, virtual screening results, and ADMET predictions are most useful when they are connected with measurable biochemical or cellular readouts.

  • Confirm whether designed compounds show real target activity
  • Compare potency across analogs and candidate series
  • Evaluate selectivity, cytotoxicity, and developability risks
  • Use wet-lab data to guide the next design and optimization round

Biochemical Activity Assays

Support includes: enzyme inhibition, receptor binding, kinase activity, protease activity, protein-ligand interaction assays, and target-specific biochemical testing for prioritized compounds.

Hit Confirmation and Dose-Response Testing

Support includes: confirmation testing of selected hits, IC50/EC50 estimation, replicate testing, positive and negative control selection, and preliminary potency ranking.

Cell-Based Functional Assays

Support includes: cell viability, pathway activity, reporter assays, phenotypic readouts, antiviral or anticancer activity, target engagement, and preliminary cellular efficacy evaluation.

Selectivity and Counter-Screening

Support includes: related-target comparison, off-target risk evaluation, orthogonal assay planning, cytotoxicity counterscreens, and prioritization of compounds with cleaner activity profiles.

Early ADME and Developability Testing

Support includes: solubility, microsomal stability, plasma protein binding, permeability, CYP-related evaluation, hERG risk follow-up, and early developability-oriented compound triage.

Compound Sourcing and Synthesis Feasibility

Support includes: purchasable analog search, make-on-demand compound selection, synthesis feasibility review, analog matrix planning, and testable compound shortlist preparation.

Integrated small molecule discovery support: computational design results can be connected with compound selection, biochemical assays, cell-based testing, dose-response analysis, selectivity profiling, ADME-related evaluation, and next-round analog design. This helps clients move from molecular design ideas to experimentally supported hit-to-lead decisions.
Discuss Experimental Validation

Related Service Modules

Structure-Based Drug DesignUse protein structures, binding pockets, and docking models to guide compound design.
Ligand-Based Drug DesignUse known active compounds, SAR, and pharmacophore models to guide analog design.
De Novo Drug DesignGenerate novel molecules, scaffold families, and property-constrained candidates.
Virtual Screening ServiceScreen large or focused compound libraries for hit discovery and prioritization.
In Silico ADMET PredictionFilter candidates by absorption, distribution, metabolism, excretion, and toxicity risks.
Binding Free Energy AnalysisCompare candidate binding strength and support high-value lead selection.

FAQ

Can the project start without an experimental protein structure?

Yes. A project may start from an AlphaFold model, homology model, known ligand series, pharmacophore hypothesis, or assay dataset. When the structure is uncertain, we usually recommend a ligand-based or hybrid workflow and clearly label structural-confidence limitations.

Can you design compounds if we only have a hit molecule?

Yes. We can analyze the hit structure, identify modifiable regions, search analogs, propose R-group modifications, evaluate physicochemical properties, and prioritize a small analog set for synthesis or purchase.

Do you provide final drug candidates ready for clinical development?

No computational workflow can guarantee clinical success. The service is designed to generate and prioritize research-stage candidates with stronger rationale for experimental validation, medicinal chemistry optimization, and downstream development.

How many compounds should be designed or screened?

The number depends on the goal. A fast feasibility project may evaluate tens to hundreds of molecules, while virtual screening may process thousands to millions of compounds. For synthesis planning, a smaller prioritized matrix is often more useful than an oversized list.

Can ADMET prediction be included before synthesis?

Yes. ADMET prediction and physicochemical filtering can be integrated early to reduce the chance of selecting molecules with poor solubility, permeability, metabolic stability, toxicity alerts, or unfavorable drug-like properties.

What information should I send for a quote?

Please send the target name, available structures, known ligands or compound files, assay data if available, desired design goal, number of compounds expected, and any property or chemistry constraints. We can suggest a staged plan if the project is still exploratory.

Ask a Small Molecule Design Expert

Online Inquiry

Submit your project details below, and our team will respond within 24 hours.

x
Need help getting the data you need?

Talk to our technical team about your project!

I Want To Talk
logo
Give us a free call

Send us an email

Menu Links
Home Services Solutions About Us Contact Us Careers Distributors
Our Services
Protein Structure Modeling Service Protein Sequence Analysis Service Drug Design Services Quantum Chemistry Service
Our Services
In Silico Protein-Protein Interactions Prediction Service Molecular Docking Service Bioinformatics Services Disease Research Services
Our Solutions
Antibody Drug Discovery Service Drug Design Service
Copyright © CD ComputaBio. All Rights Reserved.
Top